Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma (MEL37)
This study has been completed.
Sponsor:
University of Virginia
Information provided by (Responsible Party):
University of Virginia
ClinicalTrials.gov Identifier:
NCT00912418
First received: June 1, 2009
Last updated: June 17, 2013
Last verified: June 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Estimated Study Completion Date: | No date given |
| Estimated Primary Completion Date: | No date given |